61.07
Schlusskurs vom Vortag:
$59.24
Offen:
$60.48
24-Stunden-Volumen:
43.18M
Relative Volume:
1.14
Marktkapitalisierung:
$12.37B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
88.51
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
+6.10%
1M Leistung:
-5.54%
6M Leistung:
+113.91%
1J Leistung:
+146.35%
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
HIMS
Hims Hers Health Inc
|
61.07 | 12.37B | 1.78B | 164.40M | 236.51M | 0.69 |
![]()
PG
Procter Gamble Co
|
158.02 | 381.79B | 83.93B | 15.50B | 15.03B | 6.30 |
![]()
UL
Unilever Plc Adr
|
62.10 | 154.84B | 65.10B | 6.16B | 0 | 2.4569 |
![]()
CL
Colgate Palmolive Co
|
88.19 | 74.51B | 19.95B | 2.90B | 3.47B | 3.54 |
![]()
KMB
Kimberly Clark Corp
|
127.96 | 44.14B | 19.75B | 2.47B | 2.39B | 7.34 |
![]()
KVUE
Kenvue Inc
|
21.36 | 41.32B | 15.30B | 1.06B | 1.45B | 0.55 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-04 | Bestätigt | Needham | Buy |
2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
2025-01-07 | Eingeleitet | BTIG Research | Buy |
2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
2024-08-22 | Eingeleitet | Needham | Buy |
2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
2023-12-07 | Eingeleitet | Imperial Capital | In-line |
2023-07-28 | Eingeleitet | TD Cowen | Outperform |
2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-09-07 | Eingeleitet | Truist | Hold |
2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
2022-04-14 | Eingeleitet | Guggenheim | Buy |
2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
2021-12-02 | Eingeleitet | Jefferies | Hold |
2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
2021-07-06 | Eingeleitet | BofA Securities | Neutral |
2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
2021-04-21 | Eingeleitet | Truist | Hold |
2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
2021-02-17 | Eingeleitet | Citigroup | Neutral |
2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Goes Global, Named To Top Stocks List: Build Your Growth Stock Watchlist With These Just Updated Screens - Investor's Business Daily
Where Will Hims & Hers Stock Be In 10 Years? - Barchart.com
Hims & Hers Health Inc Stock: Navigating High Volatility and a Rich Valuation - Daily Chhattisgarh News
Bet on Winning DuPont Analysis & Pick 3 Top Stocks - Yahoo Finance
Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth) - Barchart.com
Hims & Hers Health Annual Stockholders Meeting Results - TipRanks
Hims & Hers (HIMS) Stock Pauses After Explosive 134% Rally This Year, Highlighting Immense Growth - Daily Chhattisgarh News
These 2 Growth Stocks Are No-Brainer Buys Right Now - Yahoo Finance
VF Corp, MGM Resorts, PENN Entertainment, Hims & Hers Health, and Camping World Shares Are Soaring, What You Need To Know - Yahoo Finance
2 Reasons To Double Down On Hims & Hers Ahead Of August (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Stock Skyrockets Over 8%, Extending a Phenomenal 147% Annual Gain - Daily Chhattisgarh News
Where are the Opportunities in (HIMS) - news.stocktradersdaily.com
Hims & Hers: An Excellent Subscription Business - Seeking Alpha
The controversial rise of Franken-pills: Telehealth companies push to mix meds in a single pill - Sherwood News
Hims & Hers (HIMS) Stock Dips Amid Profit-Taking, But Yearly Gains Exceed a Massive 134% - Daily Chhattisgarh News
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Hims & Hers Health and Sociedad Quimica y Minera de Chile have been highlighted as Zacks Bull and Bear of the Day - Zacks Investment Research
Where Will Hims & Hers Stock Be in 10 Years? - The Globe and Mail
Noteworthy Thursday Option Activity: PARR, VZ, HIMS - Nasdaq
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth - Yahoo Finance
Hims & Hers (HIMS) Share Price Shows Explosive Growth, Surging Over 150% in a Year - Daily Chhattisgarh News
June 2025's Select Stocks That Could Be Trading Below Estimated Value - simplywall.st
Hims & Hers Health’s (HIMS) Equal Weight Rating Reaffirmed at Morgan Stanley - Defense World
3 Reasons We Love Hims & Hers Health (HIMS) - Yahoo Finance
HIMS Experiences Mixed Growth in App Downloads and Web Traffic | - GuruFocus
Hims & Hers (HIMS) Stock Soars, Capping a Year of Explosive Growth - Daily Chhattisgarh News
Hims & Hers Stock Falls After Eli Lilly Rules Out Telehealth Tie-Up: Citi Calls It Aggressive Stance, Retail Turns Bearish - MSN
Hims & Hers: The ZAVA Acquisition Catapults Growth In Europe's Weight-Loss Market - Seeking Alpha
Lilly Pacts Bar Telehealth Firms From Selling Copycat Zepbound - MSN
Needham Lifts PT on Hims & Hers Health (HIMS) Stock, Maintains Buy Rating - MSN
Hims & Hers Health (NYSE:HIMS) Shares Down 1.8% on Insider Selling - Defense World
Citi Keeps Hims & Hers (HIMS) Price Target, Maintains Sell Rating - MSN
HIMS Faces Uncertain Future with Potential Eli Lilly Partnership - GuruFocus
Is Hims & Hers Health a Smart Buy Right Now? - MSN
Lilly Pacts Prohibit Telehealth Sales of Copycat Zepbound - Bloomberg.com
Hims & Hers stock falls after Lilly rules out partnership - Investing.com Australia
Lilly (LLY) Pacts Bar Telehealth Firms From Selling Copycat Zepbound - Bloomberg.com
Hims & Hers says its weight-loss business can grow as US market changes - Reuters
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLO – Is it Time to Sell? - AOL.com
Hims & Hers Health's Strategy in the Evolving Weight-Loss Drug MarketNews and Statistics - IndexBox
Hims & Hers (NYSE: HIMS) Live: Complete Earnings Coverage - AOL.com
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLOIs it Time to Sell? - 24/7 Wall St.
Hims & Hers (HIMS) Stock Stays Flat After Volatile Session, Highlighting Massive Yearly Gains - Daily Chhattisgarh News
Analysis: Hims & Hers says its weight-loss business can grow as US market changes - Yahoo Finance
Why Hims & Hers Health (HIMS) Might be Well Poised for a Surge - Yahoo Finance
Hims & Hers Health, Inc. (HIMS): A Bull Case Theory - Insider Monkey
Hims & Hers Health Unusual Options Activity - Nasdaq
Hims & Hers (HIMS) Stock Tumbles 10% in a Week, Pausing a Meteoric 160% Annual Rally - Daily Chhattisgarh News
Hims & Hers Health and AST SpaceMobile have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Rating of “Hold” from Analysts - Defense World
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hims Hers Health Inc-Aktie (HIMS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Dudum Andrew | Chief Executive Officer |
Jun 16 '25 |
Option Exercise |
2.43 |
125,335 |
304,564 |
285,550 |
Dudum Andrew | Chief Executive Officer |
Jun 16 '25 |
Sale |
56.76 |
128,127 |
7,271,950 |
160,215 |
Dudum Andrew | Chief Executive Officer |
Jun 17 '25 |
Sale |
59.22 |
65,110 |
3,855,542 |
95,105 |
Dudum Andrew | Chief Executive Officer |
Jun 16 '25 |
Sale |
56.51 |
47,534 |
2,686,300 |
237,660 |
Boughton Soleil | Chief Legal Officer |
Jun 16 '25 |
Sale |
56.80 |
5,451 |
309,617 |
165,881 |
Boughton Soleil | Chief Legal Officer |
Jun 17 '25 |
Sale |
59.75 |
2,572 |
153,677 |
163,309 |
Becklund Irene | PAO |
Jun 17 '25 |
Sale |
59.75 |
8,485 |
506,979 |
712 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):